Welcome to our dedicated page for Nucana SEC filings (Ticker: NCNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial results, cash runway projections, and pages of ProTide chemistry detail fill NuCana’s annual 20-F. Finding the one paragraph that explains a pivotal phase-2 study or spotting when an executive exercises options can feel impossible. NuCana SEC filings explained simply is exactly what investors need—and it’s what Stock Titan delivers.
Our AI highlights what matters, turning NuCana’s dense disclosures into clear, searchable insights. Whether you’re looking for NuCana insider trading Form 4 transactions, a concise view of the NuCana annual report 10-K simplified (the 20-F equivalent), or context for each NuCana 8-K material events explained, everything updates the moment EDGAR posts. Key filings and why you’ll reference them:
- Form 4: Track NuCana Form 4 insider transactions real-time and monitor executive stock transactions before critical data releases.
- 6-K / 8-K: Spot trial readouts or collaboration news woven into material events—instantly surfaced by our AI.
- 20-F (10-K equivalent): Deep-dive financials, risk factors, and pipeline timelines with a click—perfect for NuCana earnings report filing analysis.
- Quarterly updates: Investors still search for a NuCana quarterly earnings report 10-Q filing; we map every 6-K financial update to the same dashboard.
- DEF 14A proxy: Quickly locate NuCana proxy statement executive compensation data.
Want guidance on segment spending trends or understanding NuCana SEC documents with AI? Stock Titan’s expert models summarize complex pharmacology, cross-link pipeline milestones, and flag unusual option awards. Compare R&D burn quarter-over-quarter, receive alerts on NuCana executive stock transactions Form 4, and export data for modeling—no manual page-turning required.
NuCana plc furnished a Form 6-K noting it issued a press release announcing third quarter 2025 financial results and provided accompanying materials. The filing includes unaudited condensed consolidated financial statements as of September 30, 2025 (Exhibit 99.1), Management’s Discussion and Analysis for the three and nine months ended September 30, 2025 and 2024 (Exhibit 99.2), and the November 13, 2025 press release (Exhibit 99.3).
Exhibits 99.1 and 99.2 are incorporated by reference into the Company’s registration statements on Form F-3 (File No. 333-281576) and Form S-8 (File Nos. 333-223476 and 333-248135). Exhibit 99.3 is being furnished and is not deemed filed. The Company also disclosed that, effective October 21, 2025, Bali Muralidhar, M.D., Ph.D. resigned from the Board and all committees; the resignation was not the result of any dispute regarding operations, policies, or practices.
NuCana plc (NCNA) reported that the China National Intellectual Property Administration issued a new patent covering NUC‑7738’s composition of matter. The update was communicated via a press release attached as Exhibit 99.1.
The information is incorporated by reference into the company’s registration statements on Form F‑3 (File No. 333-281576) and Form S‑8 (File Nos. 333-223476, 333-248135). The press release is being furnished, not filed, under the Exchange Act.
NuCana plc furnished a Form 6-K announcing it issued a press release about new research presented at ESMO 2025. The presentation covers a model system investigating the synergistic effects of NUC-7738 and PD-1 inhibition in primary organoids derived from patients with renal cell carcinoma.
The press release is attached as Exhibit 99.1 and is incorporated by reference. The information in Exhibit 99.1 is being furnished and not deemed filed under the Exchange Act.
NuCana plc reported an update via Form 6-K, stating that on October 14, 2025 it announced the publication of new data from the NuTide:303 clinical study evaluating NUC-3373 on medRxiv, alongside complementary preclinical findings published in the peer‑reviewed journal PLOS ONE.
The company furnished a press release as Exhibit 99.1. The information is being furnished, not filed, under the Exchange Act and is not subject to Section 18 liabilities, nor incorporated into other filings except by specific reference.
Key event: On 21 Jul 2025 NuCana plc (NCNA) filed a Form 6-K reporting the cancellation of all outstanding Series A American Depositary Share purchase warrants. The move follows completion of a strategic at-the-market (ATM) execution.
The filing contains no financial statements, earnings metrics or additional material events. A press release with further details is provided as Exhibit 99.1 and incorporated by reference. The report was signed by Interim CFO Ian Webster.
- Form type: 6-K (foreign issuer current report)
- Purpose: disclose warrant cancellation
- Exhibit: 99.1 – press release dated 21 Jul 2025
No additional information on revenue, guidance, debt, litigation or operational performance was disclosed.
FAQ
What is the current stock price of Nucana (NCNA)?
What is the market cap of Nucana (NCNA)?
